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Abstract: Monoclonal antibodies (mAbs) are a
powerful immunochemical tool. Today, the
availability of mAbs with desired specificity
enables ligand separation based upon the
immunoaffinity technique. By using the high
selectivity of mAbs, immunoaffinity
purification offers the possibility of isolating
compounds even from complex samples with
a selectivity which cannot be achieved by
other methods. This paper reports the
preparation and identification of monoclonal
antibodies against human interleukin-2 (IL-2)
and the establishment of an immunoaffinity
method for purifying human IL-2 (hIL-2).

Department of Immunology, Faculty of
Medicine, Gazi University,
06500, Besevler, Ankara, Turkey

Hybridomas were generated by the fusion of
NSO or FO myelomas and spleen cells from
immunized mice. Hypoxanthine-aminopterinthymidine-resistant hybridomas secreting
antibodies specific for hIL-2 were assayed by
an ELISA and cloned using the single cell pickup technique. The monoclonal antibody of the
isotype IgM was purified from fetal calf serum
(FCS)-free supernatant of hybridoma cell
culture using ammonium sulfate precipitation
followed by size-exclusion chromatography.
The monoclonal antibody of the isotype IgG1
was purified using protein G affinity
chromatography directly from supernatant of
hybridomas cultured in medium supplemented
with IgG-depleted FCS. In order to purify
human
IL-2
by
immunoaffinity
chromatography, anti-human IL-2 IgG1 mAb
was coupled to Cyanogen Bromide-activated
Sepharose 4B gel beads.

Introduction
A monoclonal antibody (mAb) possesses a unique
specificity and an extremely high selectivity for the
epitope present on the antigen (1). Antibodies are
important tools used by many investigators in their
research and have led to many medical advances. The use
of monoclonal antibodies in biomedical research has been
and will continue to be important for the identification of
proteins, carbohydrates, and nucleic acids. Their use has
led to the elucidation of many molecules that control cell

Three monoclonal antibodies, designated CAyIL2M, CAy-IL2Mb, and CAy-IL2G, have been
produced against human interleukin-2. CAyIL2M and CAy-IL2Mb were shown to be of the
isotype IgM, and CAy-IL2G was shown to be
of isotype IgG1. Hybridoma tissue culture
supernatants were strongly positive by ELISA
at dilution of up to 1/1000. Human
recombinant IL-2 was purified by
immunoaffinity chromatography on CAy-IL2G
-Sepharose CL-4B (5x50 mm), with a
recovery of nearly 80% at a high flow rate of
0.4ml per minute. In order to prevent
substantial losses in the total antigenic
activity, the elution step was effectively
optimized. These results suggest that the antihuman IL-2 mAb established in this study is
useful for one-step purification of
recombinant human IL-2.
These mAbs have great potential for the
development of an immunoassay for
measuring human IL-2 and their application in
immunoaffinity chromatography could offer a
valuable tool for the purification of natural
human IL-2 secreted from mitogen plus lectinstimulated peripheral blood mononuclear
cells. Thus, mAbs directed against other
epitopes that might be present on native IL-2
could be obtained in the future.

Key Words: Monoclonal antibody, human
interleukin-2, immunoaffinity purification.

replication and differentiation, advancing our knowledge
of the relationship between molecular structure and
function (2-4). In addition, the exquisite specificity of
mAb allows them to be used in humans and animals for
the diagnosis and treatment of diseases (5, 6).
Interleukin-2 plays an important role in acquired
immunity (7). However, only small amounts of natural IL2 are secreted from human peripheral blood mononuclear
cells (8). Therefore, a method for an effective purification
system is needed. Separation based upon immunoaffinity
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is becoming more and more common in a large field of
applications. By using the high selectivity of biomolecules
(antibodies, receptors, specific proteins), this technique
offers the possibility of isolating compounds even from
complex samples (9).
Accordingly, this study describes the production,
characterization, and purification of anti-human IL-2
monoclonal antibodies and their application to the
purification of recombinant human IL-2 using
immunoaffinity column chromatography.

Materials and Methods
Female BALB/c mice, aged 6-8 weeks, were used for
immunization, isolating resident peritoneal macrophages
and preparation of thymocyte-conditioned medium
(TCM).
Mouse thymocytes were obtained by removing the
thymus glands from four BALB/c mice and then pressing
the organs through a stainless steel mesh. The cells were
then pooled, washed with RPMI-1640 (Sigma Sigma
6
Chemical Co. USA) and resuspended at 5x10 cells per ml
in RPMI-1640 supplemented with 20% fetal calf serum
(FCS, Seromed-Biochrom KG D-12247 Berlin, Germany).
The cells were cultured in 250ml flasks (Greiner,
Frickenhausen, Germany) for 6 days. The culture
supernatants were then harvested, centrifuged to remove
the debris and filtered through a 0.2µm filter (Schleichter
& Schuell GmbH, Dassel, Germany). The TCM was stored
at –80°C in aliquots until use.
A 6-week-old mouse (mouse 1) was immunized with
50µg of recombinant human interleukin-2 (r-h-IL-2, Lot
No: 20B06Y, Glaxo IMB, 46 routes des Acacias, 1211
Geneva 24-Switzerland) intraperitoneally every second
week. Another mouse (mouse 2) was immunized with
50µg of recombinant human interleukin-2 (r-h-IL-2,
6
IU/ml, Roche)
Proleukin, Aldesleukin, 18x10
intraperitoneally every month. Complete and incomplete
Freund’s adjuvants (Sigma) were used for the first and
second inoculations respectively. The final injection of
antigen was given in 0.09% NaCl. The spleen cells of the
animals were collected for fusion 3 days after the final
boost. Cell fusion procedure was performed as described
previously (10). Briefly, all splenocytes from mouse 1
were fused with FO myeloma cells (ATCC, American Type
Culture Collection, Rockville, Maryland, USA) and half of
the splenocytes from mouse 2 were fused with NSO
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myeloma cells (obtained from Royal Postgraduate
Medical School, London) using polyethylene glycol (Wt
3000-3700, Sigma). After fusion, cells were resuspended
in complete medium (CM) consisting of RPMI-1640 with
L-glutamine and NaHCO3 supplemented with 20% heatinactivated FCS, 10mM HEPES, 1mM sodium pyruvate,
10% TCM, and 4% non-essential amino acids (Sigma)
and then incubated in feeder cell-seeded 24-well tissue
culture plates (Greiner, Frickenhausen, Germany) at a
density of 2x106 cells per ml in an atmosphere of 5% CO2
in air at 37°C. Peritoneal resident macrophages from
non-immunized BALB/c mice were used as feeder cells at
a density of 5x104 cells per well. After incubation for 24
h, hypoxanthine-aminopterin-thymidine (HAT, Sigma)
mixture was added to the medium (11). Cultures were
subsequently fed with HAT containing complete medium.
Hybrid growth was assessed visually using an inverted
microscope. Culture supernatants were screened by
enzyme-linked immunosorbent assay (ELISA) for
antibody production.
Screening for the presence of anti-h-IL-2 mAb in the
culture supernatants of hybrid cells was performed with
lab-made ELISA. High binding capacity 96-well flatbottomed microtiter plates (Cat no: 3590, Costar,
Corning Incorporated, Corning, NY, USA) were coated
with Proleukin. To each well was added 50µl of IL-2 at
2µg/ml in phosphate buffered saline (PBS) and then they
were incubated overnight at room temperature. After
washing, potential binding sites were blocked with 200µl
of 0.3% bovine serum albumin (BSA, Sigma). Culture
supernatants, 100µl per well, were incubated for 1 h at
37°C. After washing five times with 0.03% Tween-20
containing PBS (PBS-T), to each well was added 100µl of
horse radish peroxidase (HRP)-labeled Fab-specific antimouse IgG conjugate (Sigma Chem. Co., MO, USA),
diluted to 1/6,000 in PBS-T, and then incubated for 1 h
at 37°C. After washing five times, to each well was added
100µl of TMB-chromogen/H2O2-substrate and then they
were incubated for 30 minutes at room temperature. The
reaction was stopped by adding 50µl of 2M H2SO4 per
well and then optical density (OD) was evaluated with an
ELISA reader (LP400, Diagnostics Pasteur, France) using
either a 450nm or a 450/620 nm filter.
Hybrid cell clones were obtained by picking up a single
cell with a thin-pointed pasteur pipette (hand-made)
under inspection with an inverted microscope settled in a
class II biological safety cabinet. Each hybrid cell was
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transferred to a separate well of a 96-well flat-bottomed
microtitre plate (Greiner, Germany). Single hybrid cells
were fed with CM. Supernatants from wells where only
one clone was microscopically detectable were tested for
immunoreactivity. Cells from positive clones were
propagated and then transferred into 25cm2 flasks
containing RPMI-1640 supplemented with 10% FCS.
In order to determine the isotypes of the monoclonal
antibodies produced by the hybridoma clones, a
commercially available isotyping kit (ISO-1, ImmunoType
Mouse Antibody Isotyping Kit, Sigma Chemical Co) was
used and studied according to the manufacturer’s
instructions.
Hybridoma cells were cultured at 37°C with 5% CO2
and 95% air and under fully humidified conditions. The
culture medium was RPMI-1640 supplemented with
10% FCS. Hybridoma cells were seeded at 1x104 cells per
ml in 24-well plates (Greiner, Germany) on day 0.
Ascitic fluid was obtained as described previously
(10). The IgM content of diluted and glass wool-passed
ascitic fluid was obtained using 30% saturated
ammonium sulfate (SAS) precipitation (12). A protein
pellet was resuspended in PBS and dialyzed against PBS.
Dialysate was passed through a Sephadex G-200 packed
column attached to a high-performance liquid
chromatographic (HPLC) system (Waters 650 Advanced
Protein Purification System-600E System controller,
Division of Millipore, Milford, MA, USA) equipped with a
programmable multiwavelength detector (Waters 490E)
and an interface module. A personal computer was used
to control the apparatus and the standard HPLC software
(Maxima 820 chromatography workstation) was used to
evaluate chromatographic runs. IgM containing the leader
peak was pooled and then any contaminant IgG was
completely removed by passing through a protein G
Sepharose High Performance (1 ml MAbTrap G II Kit,
Supelco Bellefonte, PA, USA) affinity column as described
previously (13). Protein concentrations in the samples
were determined by the method described elsewhere
(14) using bovine serum albumin (BSA, Sigma Chem. Co.,
MO, USA) as a standard.
CAy-IL2Mb was purified from 50 ml supernatant of
hybridomas cultured in FCS-free RPMI-1640. The initial
6
cell concentration was adjusted to 5x10 cells per ml and
then incubated for 48h. After a 50% SAS precipitation,
the protein pellet was resuspended in PBS. For desalting,

it was passed through Sephadex G-50 fine (Sigma,
packed in a 10x50mm glass column).
CAy-IL2G mAb was purified as described previously
(15). In brief, anti-human IL-2 IgG1 mAb secreting
hybridomas were cultured in RPMI-1640 supplemented
with 10% IgG-depleted FCS for 48 h. The initial cell
concentration was adjusted to 5x106 cells per ml. Nearly
50ml of supernatant was passed through 1ml protein G
column and the bound fraction was eluted with 2ml of
0.1M citric acid pH 2.6. The fraction eluted was
neutralized with 1M Trisma base.
Human IL-2 concentrations were measured with a
commercially available ELISA kit (BioSource International,
820 Flynn Road, Camarillo, California, USA). ELISA was
performed according to the manufacturer’s instructions.
CAy-IL2G was immobilized on Cyanogen Bromideactivated Sepharose 4B gel beads as described elsewhere
(16). MAb-bound gel matrix was packed in a glass column
of 5x50mm (Tosohaas, Zettachring 6, 7000 Stuttgart
80, Germany). The column was equilibrated with run
buffer (RB; 10mM PO4 buffer pH 7.2 containing 9g NaCl
per L). Then 2ml of Proleukin solution (40µg/ml) was
applied to the HPLC system-attached CAy-IL2G column at
a flow rate of 0.4ml/min. The matrix-bound fraction was
eluted with 2ml of 0.1M Glycine-HCl pH 2 at a flow rate
of 1ml/min and 3ml of the peak fraction was neutralized
with 0.5ml of 1M Trisma base.

Results
Three hybridoma cell lines were established. CAy-IL2M and CAy-IL-2Mb hybridomas were obtained by fusing
splenocytes with FO myeloma. CAy-IL-2G was obtained
by fusing splenocytes with NSO myeloma. The isotypes of
the monoclonal antibodies were found to be IgM for both
CAy-IL-2M and CAy-IL-2Mb hybridomas and IgG1 for
CAy-IL-2G hybridoma (Table 1).
Culture supernatants of CAy-IL-2G and CAy-IL-2Mb
hybridomas demonstrated a strong reaction against
proleukin-coated solid phase. However, it was not
prominent with CAy-IL2M. When hybridomas were
cultured for various periods of time, mAb concentrations
in the culture supernatants increased in a time dependent
manner (Figure 1).
The desalting of 50% SAS precipitated CAy-IL2Mb
mAb was effectively performed with Sephadex G-50 size-
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CAy-IL2M
CAy-IL2Mb
CAy-IL2G

Myeloma partner
used for fusion

Secreted mAb
specific for

Isotype of mAb
secreted

FO
FO
NSO

human IL-2
human IL-2
human IL-2

IgM
IgM
IgG1

3

CAy-IL2Mb 24 h
CAy-IL2Mb 48 h
CAy-IL2Mb 72 h
CAy-IL2M

During each application, the IgG content of 5 ml of
FCS was almost completely removed by 1 ml protein G
column. When IgG-depleted FCS (G-FCS) was re-loaded
on protein G, almost no binding occurred (data not
shown). Thus, the mAb purified from the supernatant of
hybridomas cultured in G-FCS-supplemented medium
demonstrated high purity. As shown in Figure 3, 0.1M
citric acid pH 2 buffer eluted the protein G-bound IgG1.
Almost all of the IgG1 was purified from the culture
supernatant by protein G affinity chromatography (Table
3).

OD 450/620 nm

2

1,5

1

0,5

0
0.00001

0.0001
0.001
0.01
Dilution of supernatants

0.1

1

Anti-human IL-2 secretion capacities of hybridoma cells.
Hybridomas were cultured in RPMI-1640 supplemented
with 10% FCS for various time periods. Hybridomas were
initially seeded at a concentration of 1x104 cell per ml.
Interleukin-2 level, represented as OD450/620 nm at serial
dilution, was determined using proleukin-coated solid
phase and HRP-labeled Fab-specific conjugate. Data are
represented as the mean of duplicate wells.

3.00

2.00

280 nm (x10-1)

Figure 1.

Characteristics of the hybridoma cell
lines established.

exclusion chromatography (Figure 2). As shown in Table
2, nearly all of the CAy-IL2Mb was recovered from FCSfree culture supernatant by 50% SAS precipitation
followed by desalting.

CAy-IL2G 24 h
CAy-IL2G 48 h
CAy-IL2G 72 h

2,5

Table 1.

In preliminary experiments it was determined that
0.1M Glycine-HCl pH 2 was an effective elution buffer for
releasing bound Proleukin from CAy-IL2-Sepharose
(Figure 4). At a flow rate of 0.4ml per minute, the CAyIL2G-Sepharose immunoaffinity column bound most of
the human recombinant IL-2 and the antigenic property
was maintained when the IL-2-containing peak fraction
was immediately neutralized with 1M Trisma base (Table
4).

5.00

(A)

4.00
3.00

280 nm (x10-1)

Hybridoma cell

(B)

2.00

1.00

1.00
0.00

0.00
0.00
Figure 2.
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0.50

1.00
x 101 Minutes

1.50

0.00

0.50

1.00
x 101 Minutes

1.50

Purification of CAy-IL2Mb from culture supernatant without FCS using 50% SAS precipitation followed by desalting through Sephadex G50. After centrifugation of 50% SAS-containing culture supernatant, upper layer (A) demonstrated a high content of ammonium sulfate
(second peak on A) and minute amounts of CAy-IL2Mb (compare Table 2) represented as the first peak on A. Sephadex G-50 size-exclusion
chromatography of the precipitate (B) demonstrated a high content of CAy-IL2Mb (compare Table 2), represented as the first peak on B,
and minute amounts of ammonium sulfate (second peak on B).
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Table 2.

Effectiveness of 50% SAS precipitation for purification of IgM mAb from FCS-free culture supernatant.
OD450 nm value of the samples

a

Dilution

Culture
supernatant (50ml)
(50 ml)

SAS
Supernatant
b
(100 ml)

SAS
Precipitate
c
(2 ml)

Sephadex G-50
First peak
d
(2x1.5 ml)

Sephadex G-50
Second peak
(2x2.75 ml)e

2.824
0.337
0.125
0.078
0.070
0.069

0.996
0.070
0.068
0.070
0.062
0.068

1.836
1.255
0.524
0.168
0.082
0.068

1.680
1.097
0.460
0.125
0.081
0.073

0.173
0.096
0.086
0.072
0.068
0.070

100
10-1
-2
10
-3
10
-4
10
10-5

a. Dilution was made in RPMI-1640 supplemented with 10% FCS
b. Samples were taken from the supernatant of overnight-incubated 50% SAS containing CAy-IL2Mb culture supernatant after centrifugation at
1500g for 60 minutes.
c. Samples were taken after dissolving the pellet obtained by SAS precipitation as described above.
d. Pooled fractions (from 50th second to 135th second) obtained from Sephadex G-50 chromatographic study as depicted in Figure 2.
e. Pooled fractions (from 135th second to 300th second) obtained from Sephadex G-50 chromatographic study as depicted in Figure 2.

280 nm

Discussion
2.00

Monoclonal antibodies are extensively used in basic
biomedical research, and in the diagnosis, and treatment
of illnesses such as infections and cancer. However, mAb
production technology has not been developed
satisfactorily in Turkey. Although several studies relating
to the production of mAbs have appeared in Turkish
journals during the past few years (10, 17-21), its level
is still far below what it should be.

1.50

1.00

0.00
0.00

Figure 3.

CA

0.50

2.00

4.00
x 101 Minutes

6.00

Purification of CAy-IL2G from G-FCS-supplemented culture
supernatant using protein G affinity chromatography.
Nearly all of the CAy-IL2G was recovered from 55 ml of
supernatant using 1ml protein G column (compare Table
3). Single peak on the chromatogram demonstrated that
protein G-bound CAy-IL2G was effectively eluted after
application of 2ml of 0.1M citric acid pH 2 (CA).

Before the advent of the hybridoma method,
investigators could produce only polyclonal serum
antibodies, and this required large numbers of immunized
animals for a sufficient amount of antibodies.
Development of the hybridoma technology provided
numerous advantages such as obtaining huge amounts of
specific antibodies and purification of the specific ligand in
a concentrated form with high purity.
Table 3.

OD450 nm value of the samples
Dilutiona

100
10-1
10-2
10-3
10-4
10-5
10-6

Culture supernatant
(55 ml)

Flow-through
(60 ml)b

Peak (mAb+Trisma)
(2.25+0.9 ml)c

2.824
2.854
1.987
0.357
0.100
0.097
0.074

0.156
0.083
0.084
0.069
0.074
0.074
0.077

2.638
2.620
2.854
2.456
0.692
0.375
0.233

Effectiveness of protein G affinity
chromatography for purification of
IgG1 from G-FCS-supplemented
culture supernatant.

a. Dilution was made in RPMI-1640 supplemented with 10% FCS
b. CAy-IL2G culture supernatant passed through protein G column.
c. Protein G-bound CAy-IL2G mAb eluted with 3 ml of 0.1M citric acid pH 2.6. In order to
neutralize citric acid-eluted 2.25 ml of mAb peak, 0.9 ml of 1M Trisma base was added.
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8.00

6.00

for any material to which a specific antibody can be
raised, making this procedure applicable to a wide range
of molecules of biomedical interest (22-24).
0.4 ml/min

2.00

EB

Proleukin

4.00

Three hybridomas (CAy-IL2M, CAy-IL2Mb, and CAyIL2G) were established. CAy-IL2M and CAy-IL2Mb were
found to secrete the mAb of the IgM isotype and CAyIL2G secreted the mAb of IgG1 isotype (Table 1). For
producing medium-scale (in micrograms) amounts of IgM
and IgG antibodies, the above-mentioned methods
seemed to be effective (Figures 2 and 3).

1 ml/min

0.00
2.50

Figure 4.

3.00

3.50

4.00
4.50
5.00
x 101 Minutes

5.50

Purification of recombinant human IL-2 using CAy-IL2GSepharose 4B immunoaffinity chromatography. Most of the
recombinant human IL-2 was captured by CAy-IL2G
coupled Sepharose 4B even at a high flow rate of 0.4ml per
min (compare Table 4). Recombinant human IL-2 was
effectively eluted from the matrix by 0.1M Glycine HCl pH
2 (EB). Proleukin-containing peak reserved its antigenic
property when immediately neutralized with Trisma base
(compare Table 4).

CAy-IL2G monoclonal antibody coupled to Sepharose
4B absorbed recombinant IL 2, confirming that it reacts
directly with IL-2 (Figure 4). The absorbed IL-2 could be
eluted by using 0.1M Glycine-HCl pH2, thus providing a
potential means for further immunoaffinity purification
of natural IL-2 from crude culture supernatant in future
studies.
Correspondence author:
Cemalettin AYBAY

This study was performed to produce anti-human IL2 mAbs for multi-purpose usage. Among the purposes
was the purification of human IL-2 by immunoaffinity
chromatography. Immunoaffinity separations can be used

Department of Immunology,
Faculty of Medicine, Gazi University,
06500, Besevler, ANKARA
Table 4

OD450 nm value of the samples
Dilutiona
10-3
10-4
-5
10

Loaded sample
(2 ml)b

Flow-through
(4 ml)c

Peak (mAb+Trisma)
(3+0.5 ml)d

Overflow
0.201
0.126

0.326
0.118
0.103

0.911
0.152
0.110

Effectiveness of CAy-IL2G-Sepharose
immunoaffinity chromatography for
purification of recombinant human
IL-2.

a. Dilution was made in sample diluent buffer of the kit.
b. Proleukin at 40µg/ml in PBS.
c. Pooled fractions (from 34th second to 44th second at a flow rate of 0.4ml/min) obtained from
the study depicted in Figure 4.
d. Pooled fractions (from 51th second to 54th second at a flow rate of 1ml/min) obtained from
the study depicted in Figure 4.
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